Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how consistent survival data from the LEAP-002 study reaffirms lenvatinib’s value in first-line treatment of ...

Adding atezolizumab and bevacizumab to TACE can improve outcomes in previously untreated, unresectable HCC, data suggest.